Here’s why this leading EU Investor turned to NASH

01/03/2016 - 4 minutes

Akarna Therapeutics (US & UK) just raised $15M (€13M) in a series B round led by Forbion Partners – one of the leading VCs from Europe.
forbion_akarna_nash_liver_diseaseAlso run by existing New York investors New Science Ventures and Third Point, the round purpose was to raise funding to develop a new drug for the liver disease Non-alcoholic steatohepatitis (NASH).

I had a chat with Marco Boorsma, a partner at Forbion (which is based in the Netherlands), to better understand why they did this investment and why now.


So, what’s your feeling on NASH?

NASH should be a really big indication in the future (it already affects 30 million patients worldwide) and as such, a potential billion euro market. Essentially NASH is related to our Western-style of living and is closely linked to diabetes and obesity. And as both are growing in our western society, NASH should grow as well.

The most surprising in this disease is that there is no drug approved yet.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: